| Recruitment status | Main results already published |
| Unique ID issued by UMIN | UMIN000003007 |
| Receipt No. | R000003642 |
| Official scientific title of the study | Japanese Aortic Stenosis Study-2 |
| Date of disclosure of the study information | 2010/04/01 |
| Last modified on | 2018/01/15 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | Japanese Aortic Stenosis Study-2 | |
| Title of the study (Brief title) | JASS-2 | |
| Region |
|
|
| Condition | ||
| Condition | patients with atrial fibrillation and warfarin usage, patients with cardiovascular diseases and without warfarin prescription | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate effects of warfarin on aortic valve calcification, and to clarify medications which effectively inhibit aortic valve calcification induced by warfarin |
| Basic objectives2 | Pharmacodynamics |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | aortic valve calcification |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | patients with atrial fibrillation and warafarin usage, patients with cardiovascular diseases and without warfarin prescription | |||
| Key exclusion criteria | no | |||
| Target sample size | 600 | |||
| Research contact person | |
| Name of lead principal investigator | Kazuhiro Yamamoto |
| Organization | Tottori University |
| Division name | Division of Molecular Medicine and Therapeutics |
| Address | 86 Nishi-cho, Yonago, Japan |
| TEL | 0859-38-6517 |
| ykazuhiro@med.tottori-u.ac.jp | |
| Public contact | |
| Name of contact person | Kazuhiro Yamamoto |
| Organization | Tottori University |
| Division name | Division of Molecular Medicine and Therapeutics |
| Address | 86 Nishi-cho, Yonago, Japan |
| TEL | 0859-38-6517 |
| Homepage URL | |
| ykazuhiro@med.tottori-u.ac.jp | |
| Sponsor | |
| Institute | Tottori University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Japan Heart Foundation |
| Organization | |
| Division | |
| Category of Funding Organization | Non profit foundation |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Main results already published | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | http://www.thrombosisresearch.com/article/S0049-3848(17)30543-1/fulltext |
| Results | Despite higher atherosclerotic risks in the non-warfarin group, 2 or 3 newly calcified leaflets emerged during 4 years in 18.0% of patients in the warfarin group and in 6.9% in the non-warfarin group (p=0.014). Aortic valve area did not significantly change in the non-warfarin group during the follow-up, but tended to decrease in the warfarin group (p=0.057). Non-vitamin K antagonist oral anticoagulant got available in Japan after this study started, and warfarin was discontinued in 15 patients of the warfarin group. The reduction of aortic valve area was significant in the remaining 107 patients on the continuous warfarin treatment (p=0.002). |
| Other related information | prospective observational study |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003642 |